Literature DB >> 9484745

In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine.

G T Shin1, A Khanna, R Ding, V K Sharma, M Lagman, B Li, M Suthanthiran.   

Abstract

BACKGROUND: Transforming growth factor-beta1 (TGF-beta1) is an immunoregulatory and fibrogenic cytokine. In an earlier in vitro study, we demonstrated that cyclosporine (CsA) increases TGF-beta1 transcription rate in human T lymphocytes. Herein, we explored whether CsA augments the in vivo expression of TGF-beta1 in humans.
METHODS: The inherent difficulty in studying the in vivo effect of CsA in humans was circumvented by investigating stable end-stage renal disease patients who were preconditioned with CsA before their living donor renal transplantation. Sera and peripheral blood mononuclear cells were obtained from CsA-preconditioned patients and quantified for TGF-beta1 expression at the mRNA (by competitive polymerase chain reaction) and protein (sandwich enzyme-linked immunosorbent assay) levels.
RESULTS: Our studies demonstrated a significant increase in TGF-beta1 expression after CsA therapy. The stimulatory effect was unique to TGF-beta1, and CsA did not increase interleukin (IL)-10, IL-6, IL-2, or tumor necrosis factor-alpha expression.
CONCLUSIONS: Our first-time demonstration of a TGF-beta1-selective in vivo stimulatory effect of CsA in humans: (1) advances a TGF-beta1-centered hypothesis for the beneficial (immunosuppression) and detrimental (fibrosis, hypertension) effects of CsA use, and (2) broadens the mechanism of immunosuppressive action of CsA to include heightened expression of an endogenous immunosuppressive cytokine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484745     DOI: 10.1097/00007890-199802150-00003

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  13 in total

1.  Sequential observations show upregulation of TGF-beta1 at the early phase of chronic small bowel rejection in rats.

Authors:  Haiyun Zhang; Yousheng Li; Jian Wang; Bin Lu; Bin Wang; Qiurong Li; Jieshou Li
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

2.  The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations.

Authors:  Hongbo Wang; Bartosz Grzywacz; David Sukovich; Valarie McCullar; Qing Cao; Alisa B Lee; Bruce R Blazar; David N Cornfield; Jeffrey S Miller; Michael R Verneris
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

Review 3.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 4.  The challenge of renal function in heart transplant children.

Authors:  Sylvie Di Filippo; Pierre Cochat; André Bozio
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

Review 5.  Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: interrogation by urinary cell mRNA profiling.

Authors:  Thangamani Muthukumar; John R Lee; Darshana M Dadhania; Ruchuang Ding; Vijay K Sharma; Joseph E Schwartz; Manikkam Suthanthiran
Journal:  Transplant Rev (Orlando)       Date:  2014-05-27       Impact factor: 3.943

6.  Post-transplantation encapsulating peritoneal sclerosis in a pediatric patient.

Authors:  Nicole da Silva; Sofia Rocha; Liliana Rocha; Sameiro Faria; Teresa Costa; Conceição Mota
Journal:  Pediatr Nephrol       Date:  2012-04-24       Impact factor: 3.714

7.  Cyclosporine A-induced neck fibrosis in a patient with adult-onset Still's disease.

Authors:  Senol Kobak; Recep Savas; Fahrettin Oksel; Eker Doganavsargil
Journal:  Clin Rheumatol       Date:  2009-09-08       Impact factor: 2.980

8.  Application of sustained delivery microsphere of cyclosporine A for preventing posterior capsular opacification in rabbits.

Authors:  Cheng Pei; Yi Xu; Jean Xin Jiang; Li-Jun Cui; Li Li; Li Qin
Journal:  Int J Ophthalmol       Date:  2013-02-18       Impact factor: 1.779

9.  Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients.

Authors:  Kelly A Harradine; Katie Ridd; Elise F Saunier; Frederic F Clermont; Jesus Perez-Losada; Dan H Moore; Ervin H Epstein; Boris C Bastian; Rosemary J Akhurst
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

10.  Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage.

Authors:  M Suthanthiran; B Li; J O Song; R Ding; V K Sharma; J E Schwartz; P August
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.